Fortrea Holdings Inc. FTRE R2KR3KPHARMA
Company Overview
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.72B (+1.0% YoY); net profit $-986.20M.
- Trailing 12 Months Year-on-year growth — revenue -4.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -2.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -2.85% |
| 1 Year: | -4.50% |
Stock Price Performance
| 1 Year: | +125.77% |
| 6 Months: | +84.18% |
| 3 Months: | +10.07% |
| 1 Month: | +0.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)45.26 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -2.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FTRE Fortrea Holdings Inc. R2KR3KPHARMA | 17.70 | -21.33 | $1.68B | 0.00% | -48.41% | -15.30% | -2.85% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 793.10M | 762.30M | 693.90M | 725.10M | 713.80M | 662.10M | 662.40M | - | - | 651.30M | 710.30M | 701.30M | 660.50M | 636.50M | 678.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 534.80M | 576.80M | 578.60M | 529.40M | 512.90M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 116.50M | 133.50M | 122.70M | 131.10M | 123.60M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 141.30M | 144.40M | 126.40M | 122.30M | 120.30M | - |
| Operating Income | - | 71.20M | 68.90M | 14.10M | 31.60M | 10.30M | -37.40M | -50.90M | - | - | -24.80M | -10.90M | -3.70M | 8.80M | 3.30M | 14.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -506.20M | -327.80M | 13.50M | 6.90M | 26.60M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 22.30M | 23.30M | 22.60M | 23.20M | 19.10M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -548.00M | -370.70M | -28.70M | -35.60M | -12.30M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 14.90M | 4.20M | -12.80M | -3.10M | 11.30M | - |
| Net Income | 32.50M | 66.40M | 60.60M | 12.50M | 30.80M | -14.00M | -101.00M | -138.40M | - | - | -562.90M | -374.90M | -15.90M | -32.50M | -23.60M | -13.20M |
| Diluted EPS | - | 0.75 | 0.68 | 0.14 | 0.35 | -0.16 | -1.13 | -1.55 | - | - | -6.25 | -4.14 | -0.17 | -0.35 | -0.25 | -0.14 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.06B | 2.84B | 2.84B | 2.70B | 2.72B |
| Operating Income | 114.30M | 187.10M | 32.00M | -161.90M | -872.60M |
| Net Income | 98.00M | 186.20M | -25.20M | -328.50M | -986.20M |
| Diluted EPS | 1.10 | 2.09 | -0.29 | -3.67 | -10.81 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 4.29B | 4.33B | 3.58B | 2.72B |
| Current Assets | - | - | 1.25B | 1.25B | 948.20M | 897.20M |
| Cash & Equivalents | - | - | 112.00M | 108.60M | 118.50M | 174.60M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 449.20M | 420.20M | 156.50M | 113.60M |
| Total Liabilities | - | - | 945.30M | 2.62B | 2.22B | 2.15B |
| Current Liabilities | - | - | 699.00M | 778.40M | 949.50M | 913.30M |
| Long Term Debt | - | - | - | 1.57B | 1.05B | 1.05B |
| Total Debt | - | - | 63.40M | 1.67B | 1.20B | 1.12B |
| Total Equity | 3.29B | - | 3.34B | 1.71B | 1.36B | 563.50M |
| Shares Outstanding | - | - | 88.80M | 88.80M | 89.70M | 93.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | 169.80M | 82.70M | 168.40M | 262.80M | 113.50M |
| Investing Cash Flow | -26.20M | -54.00M | -31.80M | 251.60M | 14.40M |
| Financing Cash Flow | -128.50M | -6.30M | -140.80M | -497.80M | -76.30M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | 3.7% | 6.6% | 1.1% | -6.0% | -32.0% |
| Net Margin % | 3.2% | 6.6% | -0.9% | -12.2% | -36.2% |
| ROE % | - | 5.6% | -1.5% | -24.1% | -175.0% |
| ROCE % | - | 5.2% | 0.9% | -6.2% | -48.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.61% | 15.80M | $297.18M |
| 2 | Goldman Sachs Group Inc | 8.85% | 8.41M | $158.27M |
| 3 | Sessa Capital IM, L.P. | 4.83% | 4.59M | $86.40M |
| 4 | Vanguard Capital Management LLC | 4.40% | 4.18M | $78.65M |
| 5 | Vanguard Portfolio Management LLC | 4.01% | 3.82M | $71.79M |
| 6 | State Street Corporation | 3.98% | 3.78M | $71.18M |
| 7 | FMR, LLC | 3.83% | 3.65M | $68.60M |
| 8 | Corvex Management LP | 3.14% | 2.99M | $56.21M |
| 9 | AQR Capital Management, LLC | 3.13% | 2.98M | $56.06M |
| 10 | Geode Capital Management, LLC | 2.68% | 2.55M | $47.90M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FTRE
Fortrea (FTRE) Stock Is Up, What You Need To Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOLVRNdGxaemF5TUxiQkp4TXNEMWYydlFYOEI3eV9GUFFpT0luMjBIclFkV1BJbENLQjBwbGJ6b1NMWjEwdGVwaXBvRjExVk8zcDViT1pfWUZkUERKT0J4U3NiOUdiRkM4Y0h0Rkh1VXlLVDQxOGluM2ZCNGY4YzlhanhGeFQ4UEFKdjJBNl…
Fortrea (FTRE) Stock Is Up, What You Need To Know - Barchart.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNb1djNFJIMEctOVhVVm4wR1RIZlZ5T1JCQnpyLU9qMjl3WldtRGFqODRqRTNIcWF1MnRyUW1ScUFfVVVvVkdLa2pPWFVZZjBHOGsxNUlFSWV3bkJqYWtDV2RiNDdPOXdLbGM4dTdfbTdpV01hQ2ZNZ3F0LVFzcThza0U1ZTZKaEVMakdac0…
Fortrea Holdings Inc. (NASDAQ:FTRE) Receives Average Rating of "Hold" from Analysts - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOZmpvTXJvajh6M0N0Y205TWowRW9jcUZBZENWaG5mMEJ1TDJMQnQtMVVTUnNGT2E2SlFNQWRmYmFLbEdmSGFXR1hFMEdZcUljRlpxbnBQZld0UC1uSDExb180M3JZWWl3QTd1SUNrNktuOVpxOVhkRGhQcHRsM3NGX0FXdzZUa3AwMGJ1ZD…
Fortrea: A Surprising M&A Move During The Recovery (NASDAQ:FTRE) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOckc1a1h4X29oQXVUU3E5SnNva2FMM0w3NUkzM0ZucWF4Vk9NVFR4SlMyenUyRDdKRExYOXhua19EYlhQa0xlYWlkTUdhSC1RRzhJbnd4UnhJUjJralR6UkYtak1qNjhUZnRhem5KR2R1b1ZPRk5nVWlueml2U3hQbjJfTnFhM3VlUm9fdT…
A 200-bed study unit and Texas lab are set to change hands. Fortrea plans to buy them for about $45M. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQVmVib1hjNHM3MUtjYWoxVDVtTnhvX2k4TXFRcXV3bERwSVpsLWFZWGd4RTlGWGttaUdHZm16Yjh6LS1uakhnVVdFUEVhNDhINk5GRkJ1YkR4dUV1NzhLa3FTTmlWOXZoVVUycm55Z2dVYUtaZV91cWhoMVg3WF9BWnFnTFowTHg2OXo5QV…
Price-Driven Insight from (FTRE) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNN0hrQlRRT3pLMHlVUWU0c1JOcVY1YnpVN25RTFhIV3gxWnFkOVVHeDNiWGZNUUg1OS1ELVFncWY0WFdqajNydlk3LTNEdU9JblFGQTRybWJHSjJqOThnakplb002eFQtdlptMjFmeFdxXzFWZ3hTNmR3V0YtRHdSd2xNVk44dlo5LVEzb0…
FTRE — Frequently Asked Questions
What is the current share price of Fortrea Holdings Inc. (FTRE)?
As of 2026-09-07 16:24 PDT, Fortrea Holdings Inc. (FTRE) trades at $17.70 on NasdaqGS. Its 52-week range is $7.73 to $20.70.
What is the market capitalisation of FTRE?
Fortrea Holdings Inc. (FTRE) has a market capitalisation of $1.68B on NasdaqGS.
What is the P/E ratio of FTRE?
FTRE trades at a trailing price-to-earnings (P/E) ratio of -21.33. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.34.
What is the return on equity (ROE) of FTRE?
FTRE has a return on equity (ROE) of -15.30%. Its return on capital employed (ROCE) is -48.41%.
Is FTRE a good stock to buy?
This page provides a data-driven analysis of Fortrea Holdings Inc. (FTRE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.